Prescribed to Fail: How Step Therapy Forces Patients Through Treatments That Don't Work Before Covering the Ones That Do

When a physician writes a prescription, the expectation is straightforward: the patient fills it, takes it, and ideally improves. But for millions of Americans covered by commercial health insurance, that chain of events is routinely interrupted by a policy their insurer controls and their doctor never approved — one that requires patients to try a sequence of cheaper alternatives before the originally prescribed treatment will be covered at all.

The practice is known formally as step therapy. Informally, and with considerable frustration, patients and clinicians call it fail-first. The name is not an exaggeration.

What Step Therapy Actually Requires

Step therapy is a utilization management tool through which insurers require a patient to attempt — and typically demonstrate inadequate response to — one or more lower-cost medications before authorizing coverage of the treatment a physician has already determined is most appropriate. The insurer, not the treating physician, defines the sequence.

In practice, this means a rheumatologist who prescribes a biologic medication for a patient with severe rheumatoid arthritis may find that the insurer will not cover it until the patient has tried and failed two or three conventional disease-modifying drugs first. A psychiatrist who prescribes a specific antidepressant based on a patient's history of prior medication failures may be overruled by a formulary algorithm that requires the patient to fail again before the prescribed drug is authorized.

The drugs required in step therapy protocols are generally less expensive for the insurer — often older generics or therapeutically adjacent medications whose patents have long expired. The financial logic is transparent: if a meaningful percentage of patients respond adequately to a cheaper drug, the insurer avoids covering the more costly one. What is less transparent is the human cost of the patients who do not respond — and who must deteriorate before the system acknowledges that reality.

The Patient Experience: Delays Measured in Suffering

Consider the experience of patients with moderate-to-severe inflammatory conditions, where the window for preventing irreversible joint damage is clinically significant. A step therapy protocol that requires a three-to-six-month trial of a medication the treating physician has already assessed as unsuitable does not merely inconvenience the patient. It may allow disease progression that could have been arrested.

Similar dynamics play out across therapeutic categories. Patients with treatment-resistant depression who have documented histories of failed medication trials may be required to repeat that failure under a new insurer's protocol. Individuals managing chronic neurological conditions may be cycled through medications that carry known tolerability concerns before reaching a drug their neurologist considers first-line.

The emotional toll compounds the medical one. Patients describe the experience as being disbelieved — a sense that an insurer's spreadsheet has been granted more clinical authority than their physician's judgment. Advocacy organizations that work with patients navigating chronic illness consistently report that step therapy denials are among the most demoralizing administrative barriers their constituents face.

What Insurers Say — and Where the Argument Falls Short

Insurers defend step therapy on several grounds. They argue that many patients do respond adequately to first-step medications, that the protocols are informed by clinical evidence, and that cost containment is a legitimate mechanism for keeping premiums manageable across the insured population.

These arguments are not entirely without merit. Formulary management does serve a function in a system where drug prices are largely unregulated, and not every step therapy protocol is medically unreasonable.

However, critics — including professional medical associations, patient advocacy groups, and a growing number of state legislators — point to several structural problems. First, step therapy protocols are designed by insurers and pharmacy benefit managers, not by treating physicians with knowledge of individual patient history. Second, the criteria for what constitutes a "failed" trial are often defined by the insurer rather than the prescribing clinician. Third, the appeals process for bypassing step therapy requirements is frequently opaque, time-consuming, and inconsistently applied.

Perhaps most critically, the protocols are static in ways that clinical reality is not. A patient who failed a particular drug class five years ago under a previous insurer may be required to fail it again under a new plan's protocol — because the documentation of prior failure does not automatically transfer, and because the insurer's algorithm does not account for it.

Legislative Responses: Uneven but Expanding

Recognizing the harm that rigid fail-first mandates can cause, a substantial number of states have enacted step therapy reform legislation. These laws vary in scope but generally share a common framework: they require insurers to establish a clear, timely exception process through which physicians can request that a patient be exempted from step therapy requirements based on clinical criteria.

As of recent legislative sessions, more than thirty states have passed some form of step therapy override legislation. The criteria that typically qualify a patient for an exception include prior failure of the required step medications, a documented contraindication, a clinical determination that the step medication is likely to cause adverse effects, or a situation in which a patient's condition is stable on a current treatment and switching would pose medical risk.

At the federal level, the Safe Step Act has been introduced in multiple congressional sessions with bipartisan support, aiming to establish similar protections for patients enrolled in employer-sponsored health plans governed by federal law — a population not covered by most state-level protections. Passage has remained elusive, but advocacy pressure continues.

Medicare Advantage plans, which are administered by private insurers under federal contract, have also drawn scrutiny for step therapy practices, particularly following rule changes that permitted these plans to apply step therapy to certain physician-administered drugs. Ongoing federal oversight efforts have sought to ensure that exception processes within Medicare Advantage are functional and not merely nominal.

What Patients Can Do Right Now

If you or a family member has received a step therapy requirement that conflicts with your physician's recommendation, several practical steps are available.

Request the insurer's clinical criteria in writing. Insurers are generally required to provide the specific criteria used to establish and apply step therapy protocols. Reviewing these criteria can help your physician frame a more targeted exception request.

Work with your physician to file a step therapy exception or prior authorization override. Most state laws that address step therapy require insurers to process exception requests within defined timeframes — often 72 hours for urgent cases. Your physician's documentation of medical necessity, prior treatment history, and clinical rationale is central to this process.

File an internal appeal if the exception is denied. Insurers are required to have an internal appeals process. A denial at the exception stage is not a final determination.

Request an external review. If the internal appeal is unsuccessful, most states provide access to independent external review, in which a clinician not affiliated with the insurer evaluates the case. External reviewers overturn insurer denials at meaningful rates.

Contact your state insurance commissioner. If your insurer is not complying with applicable state step therapy laws — particularly regarding exception timelines — the state insurance department is the appropriate regulatory body.

Consult a patient advocate. Many hospitals and academic medical centers employ patient advocates or case managers who have experience navigating insurance disputes. Independent patient advocacy organizations also offer guidance at no cost.

A System That Defaults to Doubt

Step therapy reflects a broader structural tension within American health insurance: a system in which the financial interests of insurers and the clinical interests of patients are not always aligned, and in which the administrative burden of that misalignment falls disproportionately on patients and their physicians.

For patients managing serious or complex conditions, a protocol that requires documented failure is not a neutral inconvenience. It is a medically consequential delay — one that can mean months of inadequate treatment, preventable deterioration, and the particular frustration of knowing that a better option exists but remains just out of reach.

Understanding the mechanism, knowing the exception pathways, and advocating persistently are not perfect solutions to a flawed system. But they are the tools currently available — and using them effectively can make a material difference in how quickly patients reach the care their physicians have determined they need.